NCT00740636 - Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Lung Cancer

Interventions

DRUG

Temozolomide

Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.

DRUG

Temozolomide

Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.

Trial Locations (5)

Memorial Sloan-Kettering Cancer Center, New York

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre

Memorial Sloan-Kettering Cancer Center at Commack, Commack

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow